146ml

Comments

Transcription

146ml
IMPACT OF ANORO® ELLIPTA® ON
LUNG FUNCTION
RF/UCV/0035/15l Date of preparation: March 2016
© 2001-2015 GSK group of companies. All rights reserved. Anoro was developed in collaboration with Theravance Inc
ANORO® ELLIPTA® DELIVERS SUPERIOR LUNG FUNCTION VS PLACEBO AND
ITS INDIVIDUAL COMPONENTS: UMECLIDINIUM (UMEC) AND VILANTEROL (VI)1
Mean change from baseline in trough FEV11,2
Anoro Ellipta 55/22mcg
delivered a 167ml
improvement vs placebo
at day 169 (p<0.001)
Note: VI is not licensed as monotherapy for COPD
1. Donohue JF et al. Respir Med 2013; 107: 1538-1546. 2. Anoro Ellipta SmPC, April 2015.
RF/UCV/0035/15l Date of preparation: March 2016
© 2001-2015 GSK group of companies. All rights reserved. Anoro was developed in collaboration with Theravance Inc
ANORO® ELLIPTA® DELIVERS SUPERIOR LUNG FUNCTION VS TIOTROPIUM
Change from baseline in trough FEV1 in maintenance-naïve† patients at Day 169 (pooled data from studies DB2113360,
DB2113374 & ZEP117115)1
Anoro Ellipta 55/22mcg
delivered a 146ml
improvement vs
tiotropium (p<0.001)
Based on a post hoc, pooled sub-group analysis of maintenance-naïve patients from three 24-week, randomised, doubledummy, active-controlled, blinded, multi-centre, parallel-group studies. Primary endpoint: trough FEV1 on Day 169.3,4 MCID:
minimum clinically important difference, 100mL.2
†Not previously treated with a long-acting bronchodilator.
References: 1. Data on file: RF/UCV/0112/15. 2. Donohue JF. COPD 2005; 2:111–124. 3. Decramer M et al. Lancet Respir
Med 2014; 2:472–486. 4. Maleki-Yazdi MR et al. Respir Med 2014; 108:1752–1760.
RF/UCV/0035/15l Date of preparation: March 2016
© 2001-2015 GSK group of companies. All rights reserved. Anoro was developed in collaboration with Theravance Inc
LOCAL PRESCRIBING INFORMATION
Local market to insert prescribing information
RF/UCV/0035/15l Date of preparation: March 2016
© 2001-2015 GSK group of companies. All rights reserved. Anoro was developed in collaboration with Theravance Inc

Similar documents